Degradation and Impurity Analysis for Pharmaceutical Drug Candidates
Authors:
- Karen M. AlsanteKAKaren M. Alsante
- Steven W. BaertschiSBSteven W. Baertschi
- Michael CoutantMCMichael Coutant
- Brian L. MarquezBMBrian L. Marquez
- Thomas R. SharpTSThomas R. Sharp
- Todd C. ZeleskyTZTodd C. Zelesky
- 1 January 2011
- book chapter
- Published by Elsevier
- p. 59-169
Abstract
No abstract availableThis publication has 125 references indexed in Scilit:
- Isolation and structural elucidation of two impurities from a diacerein bulk drugJournal of Pharmaceutical and Biomedical Analysis, 2009
- Enhancement of protein sensitivity for MALDI imaging mass spectrometry after chemical treatment of tissue sectionsJournal of the American Society for Mass Spectrometry, 2008
- The use of mixed-mode ion-exchange solid phase extraction to characterize pharmaceutical drug degradationJournal of Pharmaceutical and Biomedical Analysis, 2007
- Structural identification of trace level enol tautomer impurity by on‐line hydrogen/deuterium exchange HR‐LC/MS in a LTQ‐Orbitrap hybrid mass spectrometerJournal of Mass Spectrometry, 2007
- Isolation and characterization of some potential impurities in ropinirole hydrochlorideJournal of Pharmaceutical and Biomedical Analysis, 2007
- Hydrogen exchange and mass spectrometry: A historical perspectiveJournal of the American Society for Mass Spectrometry, 2006
- Isolation and identification of novel impurities in spironolactoneJournal of Pharmaceutical and Biomedical Analysis, 2006
- Methods of Ion GenerationChemical Reviews, 2001
- Fourier transform ion cyclotron resonance mass spectrometry: A primerMass Spectrometry Reviews, 1998
- Principles and practice of drug photodegradation studiesJournal of Pharmaceutical and Biomedical Analysis, 1987